Therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors (Record no. 15817)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | a |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20211229132537.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 211229b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| 9 (RLIN) | 15202 |
| Author | Wu, Gang |
| 245 ## - TITLE STATEMENT | |
| Title | Therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and influencing factors |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.83(1), Jan-Feb |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mumbai |
| Name of publisher, distributor, etc. | Indian Journal of Pharmaceutical Science |
| Year | 2021 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 120-126p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | To explore the therapeutic effects of pembrolizumab combined with paclitaxel and cisplatin chemotherapy on advanced non-squamous non-small cell lung cancer and its in fluencing factors is the main objective. A total of 87 patients with advanced non-squamous non-small cell lung cancer treated in our hospital from October 2016 to May 2018 were enrolled and allocated into control group and observation group according to their disease conditions and willingness. Paclitaxel and cisplatin chemotherapy regimen was employed for control group, based on which pembrolizumab was used for observation group. Cellular immunity indices, cytokine indices, short-term efficacy, adverse reactions, and long-term prognosis were compared, and the factors affecting short-term ef ficacy and long-term prognosis were analyzed. After treatment, observation group exhibited increased cluster of differentiation 3+ T lymphocytes, cluster of differentiation 4+ T lymphocytes, and cluster of differentiation 4 +/cluster of differentiation 8+ ratio and decreased cluster of differentiation 8 + T lymphocytes compared with control group (p<0.05). After treatment, the levels of interleukin-6 and tumor necrosis factor-alpha in observation group were lower than those in control group (p<0.05). The short-term ef ficacy and long-term prognosis in observation group were better than those in control group (p<0.05), but statistically no signi ficant difference in the incidence rate of adverse reactions was found between the two groups (p>0.05). Decreased cluster of differentiation 4 +/cluster of differentiation 8+ ratio increased tumor necrosis factor-alpha level and chemotherapy were risk factors for the poor short-term efficacy and long-term prognosis in patients with advanced non-squamous non-small cell lung cancer (p<0.05), and clinical stage IV was a risk factor for the unfavorable long-term prognosis as well (p<0.05). Pembrolizumab combined with paclitaxel and cisplatin chemotherapy regimen can relieve the cellular immune suppression and alleviate inflammatory responses to improve the short-term efficacy and long-term prognosis, without raising the incidence rate of severe adverse reactions in the treatment of advanced non-squamous non-small cell lung cancer |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| 9 (RLIN) | 4639 |
| Topical term or geographic name entry element | PHARMACEUTICS |
| 773 0# - HOST ITEM ENTRY | |
| Title | Indian journal of pharmaceutical sciences |
| Place, publisher, and date of publication | New Delhi |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://www.ijpsonline.com/articles/therapeutic-effects-of-pembrolizumab-combined-with-paclitaxel-and-cisplatin-chemotherapy-on-advanced-nonsquamous-nonsmal.pdf |
| Link text | Click here |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Permanent Location | Current Location | Shelving location | Date acquired | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| School of Pharmacy | School of Pharmacy | Archieval Section | 2021-12-29 | 2021-2022634 | 2021-12-29 | 2021-12-29 | Articles Abstract Database |